Anticoagulants and Antiplatelet Drugs — MCQs

10 questions

Warfarin's mechanism of action is

The anticoagulant activity of warfarin can be reduced by all of the following except.

Which of the following clotting factors in a patient on Warfarin therapy would show the earliest decrease in functional activity?

Which of the following drugs is used for treatment of cancer associated thromboembolism?

Coagulation testing is needed for:

Following injury to a blood vessel, immediate hemostasis is achieved by:

What is the mechanism of action of ticagrelor?

Which of the following antiarrhythmic drugs is contraindicated in a patient with interstitial lung disease?

Which antilipidemic drug reduces cholesterol levels by inhibiting cholesterol absorption?

Q10

Centrineuraxial anaesthesia is not contraindicated in:

Anticoagulants and Antiplatelet Drugs Indian Medical PG Practice Questions and MCQs

Question 1: Warfarin's mechanism of action is

A. Inhibiting Vitamin K dependent carboxylation (Correct Answer)
B. Chelating calcium ions
C. Inhibiting antithrombin III activity
D. Inhibiting thrombin activity

Explanation: ***Inhibiting Vitamin K dependent carboxylation*** - **Warfarin** acts as an antagonist to **vitamin K**, competitively inhibiting the enzyme **vitamin K epoxide reductase**. - This prevents the **gamma-carboxylation** of vitamin K-dependent clotting factors (II, VII, IX, X, and proteins C and S), rendering them biologically inactive. *Chelating calcium ions* - **Calcium ions** are essential cofactors in the coagulation cascade, but warfarin does not directly affect their concentration or chelate them. - Anticoagulants that chelate calcium, such as **citrate**, are typically used *in vitro* (e.g., in blood collection tubes), not systemically. *Inhibiting antithrombin III activity* - This mechanism describes the action of **heparin** and its derivatives, which enhance the natural anticoagulant activity of **antithrombin III**. - Warfarin's primary action is on vitamin K metabolism, not on antithrombin III potentiation. *Inhibiting thrombin activity* - Direct thrombin inhibitors (**DTIs**), such as dabigatran and argatroban, directly bind to and inhibit the activity of **thrombin (factor IIa)**. - Warfarin's action is upstream in the coagulation cascade, affecting the synthesis of multiple clotting factors, including prothrombin (the precursor to thrombin).

Question 2: The anticoagulant activity of warfarin can be reduced by all of the following except.

A. Aspirin (Correct Answer)
B. Rifampin
C. Vitamin K
D. Carbamazepine

Explanation: ***Aspirin*** - **Aspirin** does NOT reduce warfarin's anticoagulant activity; instead, it increases the risk of bleeding through a synergistic effect. - Aspirin inhibits platelet aggregation via **cyclooxygenase-1 (COX-1)** inhibition, preventing thromboxane A2 formation, which is a different mechanism from warfarin's inhibition of vitamin K-dependent clotting factors. - When combined with warfarin, aspirin **potentiates** the overall antithrombotic effect and increases bleeding risk. *Carbamazepine* - **Carbamazepine** is a potent inducer of hepatic cytochrome P450 enzymes (CYP2C9, CYP3A4). - By increasing warfarin metabolism, it **reduces** warfarin's plasma concentrations and decreases its anticoagulant effect. - Patients on this combination may require higher warfarin doses to maintain therapeutic INR. *Rifampin* - **Rifampin** is one of the most potent inducers of hepatic cytochrome P450 enzymes (CYP2C9, CYP3A4). - It significantly increases warfarin metabolism, leading to **reduced** plasma concentrations and diminished anticoagulant effect. - This interaction often necessitates substantial increases in warfarin dosage. *Vitamin K* - **Vitamin K** is the direct antagonist of warfarin's mechanism of action. - Warfarin inhibits vitamin K epoxide reductase, preventing the regeneration of active vitamin K needed for synthesis of clotting factors II, VII, IX, and X. - Administration of vitamin K **reverses** warfarin's anticoagulant effect by bypassing the inhibited enzyme and restoring clotting factor production.

Question 3: Which of the following clotting factors in a patient on Warfarin therapy would show the earliest decrease in functional activity?

A. Factor VII (Correct Answer)
B. Factor IX
C. Factor X
D. Prothrombin (Factor 2)

Explanation: ***Factor VII*** - Factor VII has the **shortest half-life** (approximately 6 hours) among the vitamin K-dependent clotting factors, meaning its functional activity decreases **most rapidly** after starting warfarin therapy. - Warfarin inhibits vitamin K epoxide reductase, preventing gamma-carboxylation of **all vitamin K-dependent factors** (II, VII, IX, X). However, Factor VII's short half-life means pre-existing functional Factor VII is depleted first. - This is why **PT/INR** (which measures the extrinsic pathway dependent on Factor VII) rises before aPTT in warfarin therapy. - Reduced gamma-carboxylation impairs Factor VII's ability to bind calcium and phospholipids, essential for its activation in the extrinsic coagulation pathway. *Factor IX* - Factor IX is a **vitamin K-dependent factor** affected by warfarin, but its longer half-life (approximately 24 hours) means functional activity decreases more slowly than Factor VII. - It plays a key role in the **intrinsic coagulation pathway**. *Factor X* - Factor X is a **vitamin K-dependent clotting factor** whose gamma-carboxylation is inhibited by warfarin. - Its half-life (approximately 40 hours) is longer than Factor VII, resulting in a **slower decline in functional activity**. *Prothrombin (Factor II)* - Prothrombin (Factor II) is a **vitamin K-dependent factor** affected by warfarin. - It has the **longest half-life** (60-72 hours) among vitamin K-dependent factors, meaning its functional levels decrease most slowly after initiating warfarin therapy.

Question 4: Which of the following drugs is used for treatment of cancer associated thromboembolism?

A. Direct factor Xa inhibitors
B. Warfarin
C. Anti-thrombin III inhibitors
D. LMW heparin (Correct Answer)

Explanation: ***LMW heparin*** - **Low molecular weight heparin (LMWH)** is the **preferred anticoagulant for cancer-associated thrombosis** due to its superior efficacy. - It has a more predictable pharmacokinetic profile compared to unfractionated heparin and is administered subcutaneously. *Direct factor Xa inhibitors* - While effective for general venous thromboembolism (VTE) treatment, some direct oral anticoagulants (DOACs) like factor Xa inhibitors (e.g., rivaroxaban, apixaban) may be considered but have shown mixed results in comparative studies with LMWH for cancer patients, especially those with gastrointestinal cancers, presenting a **higher risk of major bleeding**. - **LMWH** remains the **first-line choice**, especially in patients with active cancer, given the evidence for its greater efficacy and safety profile in this specific population. *Warfarin* - **Warfarin** is generally **not recommended** as a first-line treatment for cancer-associated thromboembolism due to its **drug interactions**, need for frequent monitoring (INR), and slower onset of action. - Patients with cancer often have fluctuating nutritional status, hepatic dysfunction, and receive other medications that can significantly impact warfarin's effectiveness and safety. *Anti-thrombin III inhibitors* - **Antithrombin III inhibitors** (e.g., antithrombin concentrate) are primarily used in specific conditions like **hereditary antithrombin deficiency** or in cases of heparin resistance. - They are **not a standard treatment** for cancer-associated thromboembolism in the general population of cancer patients.

Question 5: Coagulation testing is needed for:

A. Lepirudin (direct thrombin inhibitor) (Correct Answer)
B. Dabigatran (oral anticoagulant)
C. Enoxaparin (low molecular weight heparin)
D. Fondaparinux (synthetic pentasaccharide)

Explanation: ***Lepirudin (direct thrombin inhibitor)*** - **Lepirudin**, being a direct thrombin inhibitor, necessitates **coagulation testing** (such as aPTT) to monitor its anticoagulant effect and adjust dosing, especially in patients with renal impairment. - Its narrow therapeutic window and potential for bleeding complications require careful monitoring to ensure patient safety and drug efficacy, as it lacks a specific antidote. *Dabigatran (oral anticoagulant)* - **Dabigatran** is a **direct oral anticoagulant (DOAC)** that typically does not require routine coagulation monitoring due to its predictable pharmacokinetic and pharmacodynamic profiles. - While specific tests can assess its effect in emergencies, they are not part of standard management, distinguishing it from drugs requiring regular monitoring. *Enoxaparin (low molecular weight heparin)* - **Enoxaparin**, a **low molecular weight heparin (LMWH)**, usually does not require routine coagulation monitoring in most patients due to its predictable dose-response relationship. - Monitoring with anti-Xa levels may be considered in specific populations, such as those with renal insufficiency, extremes of weight, or in pediatric and pregnant patients. *Fondaparinux (synthetic pentasaccharide)* - **Fondaparinux** is a synthetic pentasaccharide that **does not require routine coagulation monitoring** as its anticoagulant effect is highly predictable and dose-dependent. - Its action is mediated through selective inhibition of **Factor Xa**, and standard coagulation tests like aPTT or PT are not sensitive to its effects.

Question 6: Following injury to a blood vessel, immediate hemostasis is achieved by:

A. Fibrin deposition
B. Vasoconstriction (Correct Answer)
C. Platelet adhesion
D. Thrombosis

Explanation: ***Vasoconstriction*** - Following blood vessel injury, **vasoconstriction** occurs immediately, reducing blood flow and minimizing blood loss. - It is a **reflex response** mediated by local factors and neural mechanisms aiming to maintain hemostasis. *Fibrin deposition* - **Fibrin deposition** occurs later in the hemostatic process, primarily during the **coagulation phase** after initial vascular responses. - It is not an immediate response; rather, it's part of the **clot stabilization** process, requiring activation of the clotting cascade. *Thrombosis* - Thrombosis refers to the formation of a **blood clot** within a vessel, which happens after initial hemostatic mechanisms are activated. - It is not the **immediate** response post-injury; there is a sequence of events that lead to thrombosis after vasoconstriction and platelet activation. *Platelet adhesion* - Although platelet adhesion is crucial in hemostasis, it occurs following **vasoconstriction** and is not an immediate response to vessel injury [1][2]. - This process is part of the **primary hemostasis** phase, which cannot occur efficiently without prior initial vasoconstriction. **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Blood And Bone Marrow Disease, pp. 581-582. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Hemodynamic Disorders, Thromboembolic Disease, and Shock, p. 128.

Question 7: What is the mechanism of action of ticagrelor?

A. P2Y12 receptor antagonist (Correct Answer)
B. Cox inhibition
C. Inhibition of thromboxane synthase
D. GPIIb/IIIa inhibition

Explanation: ***P2Y12 receptor antagonist*** - **Ticagrelor** is an **oral antiplatelet drug** that reversibly binds to the **P2Y12 ADP receptor** on platelet surfaces. - By blocking this receptor, it prevents **ADP-mediated platelet activation** and subsequent aggregation, reducing the risk of thrombotic events. *Cox inhibition* - **COX inhibitors** like **aspirin** prevent the synthesis of **thromboxane A2**, a powerful platelet aggregator. - This mechanism is characteristic of **NSAIDs** and **aspirin**, not ticagrelor. *GPIIB/IIIA inhibition* - **GPIIb/IIIa inhibitors** (e.g., abciximab, eptifibatide, tirofiban) directly block the final common pathway for platelet aggregation by preventing **fibrinogen binding** to the GPIIb/IIIa receptor. - While also an antiplatelet mechanism, this is distinct from ticagrelor's action on the P2Y12 receptor. *Inhibition of thromboxane synthase* - Inhibition of **thromboxane synthase** would reduce the production of **thromboxane A2**, similar to the effect of COX inhibition. - This is not the primary mechanism of action for ticagrelor; drugs like **dazoxiben** or **picotamide** act through this pathway.

Question 8: Which of the following antiarrhythmic drugs is contraindicated in a patient with interstitial lung disease?

A. Amiodarone (Correct Answer)
B. Lignocaine
C. Sotalol
D. Quinidine

Explanation: ***Amiodarone*** - **Amiodarone** is contraindicated in patients with interstitial lung disease due to its well-known and potentially severe pulmonary toxicity, which can exacerbate or induce **pulmonary fibrosis**. - Its long half-life means that drug accumulation and persistent adverse effects, including **ILD exacerbation**, are significant concerns. *Sotalol* - **Sotalol** primarily carries risks of **prolonged QT interval** and **torsades de pointes** because it has both beta-blocking and Class III antiarrhythmic properties. - While it has cardiac and minor non-cardiac side effects, it is not specifically known to cause or worsen **interstitial lung disease**. *Lignocaine* - **Lignocaine** (lidocaine) is a Class Ib antiarrhythmic primarily used for **ventricular arrhythmias**, especially in acute settings. - Its adverse effects are mainly **neurological** (e.g., dizziness, seizures at high doses) and **cardiovascular** (e.g., hypotension, bradycardia), with no significant association with lung disease. *Quinidine* - **Quinidine** is a Class Ia antiarrhythmic that can cause a variety of side effects, including **gastrointestinal upset**, **cinchonism** (tinnitus, blurred vision), and **cardiac rhythm disturbances**. - While it can rarely cause a hypersensitivity pneumonitis, it is not a primary concern or contraindication in existing **interstitial lung disease** compared to amiodarone.

Question 9: Which antilipidemic drug reduces cholesterol levels by inhibiting cholesterol absorption?

A. Ezetimibe (Correct Answer)
B. Orlistat
C. Cholestyramine
D. Statins

Explanation: ***Ezetimibe*** - **Ezetimibe** selectively inhibits the **Niemann-Pick C1-Like 1 (NPC1L1) protein**, which is responsible for plant sterol and cholesterol absorption in the small intestine. - This action leads to a reduction in **LDL-C** levels by decreasing the amount of cholesterol available to the liver. *Orlistat* - **Orlistat** is a **lipase inhibitor** that prevents the absorption of dietary fats by inhibiting gastric and pancreatic lipases. - While it aids in weight loss and can indirectly improve lipid profiles, its primary mechanism is *not* direct inhibition of cholesterol absorption. *Cholestyramine* - **Cholestyramine** is a **bile acid sequestrant** that binds to bile acids in the intestine, preventing their reabsorption. - This increases the excretion of bile acids, prompting the liver to synthesize more bile acids from cholesterol, thereby lowering cholesterol levels, but it does *not* directly inhibit cholesterol absorption. *Statins* - **Statins** (HMG-CoA reductase inhibitors) are considered first-line agents for lowering cholesterol by inhibiting the **rate-limiting step in cholesterol synthesis** in the liver. - Their primary action is to reduce endogenous cholesterol production, not to block cholesterol absorption from the gut.

Question 10: Centrineuraxial anaesthesia is not contraindicated in:

A. Patient on anticoagulants
B. Raised intracranial pressure
C. Patient on aspirin (Correct Answer)
D. Platelets <80,000

Explanation: ***Patient on aspirin*** - Aspirin is an **antiplatelet agent** that irreversibly inhibits cyclooxygenase, affecting platelet function but typically does not significantly increase the risk of **epidural hematoma** to contraindicate neuraxial anesthesia. - While careful consideration is needed, especially if combined with other anticoagulants, aspirin alone usually presents a **lower bleeding risk** compared to other anticoagulants. *Patient on anticoagulants* - Use of therapeutic anticoagulants (e.g., heparin, warfarin, novel oral anticoagulants) significantly increases the risk of **spinal or epidural hematoma**, which can lead to neurological deficits. - Therefore, these medications are generally considered a **contraindication** until they are stopped and coagulation parameters are within acceptable limits. *Raised intracranial pressure* - Centrineuraxial anesthesia can decrease spinal fluid pressure, potentially exacerbating a pressure gradient and leading to **brain herniation** in patients with raised intracranial pressure. - This is a serious and potentially fatal complication, making it a **strong contraindication**. *Platelets <80,000* - A platelet count below 80,000 cells/µL indicates significant **thrombocytopenia**, increasing the risk of bleeding. - Neuraxial anesthesia is generally regarded as **contraindicated** when platelet counts are below this threshold due to the heightened risk of spinal hematoma.

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free